FEMRING

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FEMRING (FEMRING).

How it works

Femring (estradiol acetate) is a vaginal ring that releases estradiol, which binds to estrogen receptors (ERα and ERβ) in target tissues, regulating gene transcription and exerting estrogenic effects on the vaginal epithelium, urogenital tract, and other estrogen-sensitive tissues.

What the body does with it

Metabolism	Estradiol acetate is hydrolyzed to estradiol, which is metabolized primarily in the liver via cytochrome P450 (CYP) enzymes, mainly CYP3A4 and CYP1A2, to estrone and estriol; undergoes enterohepatic recirculation.
Excretion	Estradiol is primarily excreted in urine (about 90-95%) as conjugated metabolites (glucuronides and sulfates), with approximately 5-10% eliminated in feces via bile. Less than 5% is excreted unchanged.
Half-life	The terminal elimination half-life of estradiol from the vaginal ring (Femring) is approximately 36 hours. This extended half-life supports once-monthly dosing and maintains steady-state concentrations.
Protein binding	Approximately 97-99% of circulating estradiol is bound to albumin (about 60%) and sex hormone-binding globulin (SHBG, about 38%). Binding is reversible and influences free hormone levels.
Volume of Distribution	The apparent volume of distribution for estradiol is approximately 1.2 L/kg, indicating extensive distribution into tissues, including adipose tissue, breast, and reproductive organs.
Bioavailability	Femring provides systemic estradiol delivery via vaginal absorption with high bioavailability, estimated to be 50-80% relative to intravenous administration, due to avoidance of first-pass hepatic metabolism.
Onset of Action	Systemic estradiol concentrations reach therapeutic levels within 2-4 hours after vaginal ring insertion; clinical effects on vasomotor symptoms (hot flashes) are typically noted within 2-4 weeks of continuous use.
Duration of Action	Each ring provides continuous estradiol release for 90 days (3 months), with sustained therapeutic effect on menopausal symptoms throughout the entire wear period.

Classification & Brands

Dosing & administration

Insert one vaginal ring containing 0.05 mg or 0.10 mg estradiol acetate per day; replace every 3 months.

Dosage form	INSERT, EXTENDED RELEASE
Renal impairment	No dosage adjustment required in renal impairment.
Liver impairment	Contraindicated in patients with hepatic impairment; no dosage adjustment guidelines available.
Pediatric use	Not indicated for pediatric use; safety and efficacy not established.
Geriatric use	Use with caution; lowest effective dose recommended; limited data in women >65 years.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FEMRING (FEMRING).

Breastfeeding	Estradiol is excreted in breast milk. M/P ratio not established. May reduce milk production and quality. Use while breastfeeding is contraindicated.
Teratogenic Risk	Estradiol is teratogenic. Use during pregnancy is contraindicated. First trimester exposure associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure may cause urogenital abnormalities and feminization of male fetuses.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Use progestin in women with a uterus; Femring is not recommended in women with a uterus. Also, estrogens should not be used to prevent cardiovascular disease or dementia.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-sensitive neoplasia (e.g., endometrial cancer)","Active or history of venous thromboembolism (e.g., DVT, PE)","Active or recent arterial thromboembolic disease (e.g., stroke, MI)","Liver impairment or disease (e.g., acute hepatitis, impaired liver function)","Known hypersensitivity to estradiol acetate or any component of Femring","Known or suspected pregnancy"]

Clinical Precautions

Precautions

["Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism) – increased risk","Malignancy (endometrial, breast, ovarian) – increased risk","Dementia – possible increased risk in women ≥65 years","Gallbladder disease","Hypertriglyceridemia","Fluid retention","Hypocalcemia in hypoparathyroidism","Exacerbation of endometriosis","Hereditary angioedema","Ocular abnormalities (e.g., retinal vascular thrombosis)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

FEMRING

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FEMRING (FEMRING).

How it works

What the body does with it

Metabolism	Estradiol acetate is hydrolyzed to estradiol, which is metabolized primarily in the liver via cytochrome P450 (CYP) enzymes, mainly CYP3A4 and CYP1A2, to estrone and estriol; undergoes enterohepatic recirculation.
Excretion	Estradiol is primarily excreted in urine (about 90-95%) as conjugated metabolites (glucuronides and sulfates), with approximately 5-10% eliminated in feces via bile. Less than 5% is excreted unchanged.
Half-life	The terminal elimination half-life of estradiol from the vaginal ring (Femring) is approximately 36 hours. This extended half-life supports once-monthly dosing and maintains steady-state concentrations.
Protein binding	Approximately 97-99% of circulating estradiol is bound to albumin (about 60%) and sex hormone-binding globulin (SHBG, about 38%). Binding is reversible and influences free hormone levels.
Volume of Distribution	The apparent volume of distribution for estradiol is approximately 1.2 L/kg, indicating extensive distribution into tissues, including adipose tissue, breast, and reproductive organs.
Bioavailability	Femring provides systemic estradiol delivery via vaginal absorption with high bioavailability, estimated to be 50-80% relative to intravenous administration, due to avoidance of first-pass hepatic metabolism.
Onset of Action	Systemic estradiol concentrations reach therapeutic levels within 2-4 hours after vaginal ring insertion; clinical effects on vasomotor symptoms (hot flashes) are typically noted within 2-4 weeks of continuous use.
Duration of Action	Each ring provides continuous estradiol release for 90 days (3 months), with sustained therapeutic effect on menopausal symptoms throughout the entire wear period.

Classification & Brands

Dosing & administration

Insert one vaginal ring containing 0.05 mg or 0.10 mg estradiol acetate per day; replace every 3 months.

Dosage form	INSERT, EXTENDED RELEASE
Renal impairment	No dosage adjustment required in renal impairment.
Liver impairment	Contraindicated in patients with hepatic impairment; no dosage adjustment guidelines available.
Pediatric use	Not indicated for pediatric use; safety and efficacy not established.
Geriatric use	Use with caution; lowest effective dose recommended; limited data in women >65 years.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FEMRING (FEMRING).

Breastfeeding	Estradiol is excreted in breast milk. M/P ratio not established. May reduce milk production and quality. Use while breastfeeding is contraindicated.
Teratogenic Risk	Estradiol is teratogenic. Use during pregnancy is contraindicated. First trimester exposure associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure may cause urogenital abnormalities and feminization of male fetuses.
Fetal Monitoring